Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032
David C. Smith, Cathy M. Tangen, Peter J. Van Veldhuizen, Grant W. Harrer, Ali Golshayan, Glenn M. Mills, Nicholas J. Vogelzang, Ian M. Thompson, Maha H.A. Hussain
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032'. Together they form a unique fingerprint.